"LAAM (levo-alpha-acetylmethadol) is no longer approved for use in Europe and is not available for clinical use in the United States. In Europe, reports of several cases of ventricular tachycardia (torsade de pointes: TdP) occurring in patients treated with LAAM led the European Medicines Evaluation Agency (EMEA) to suspend authorization for its marketing in 2001. In the same year, responding to the reports of LAAM-related cases of TdP, the United States Food and Drug Administration (FDA) required the addition of a ‘black box’ warning on the LAAM label. The label states that LAAM should be used only for patients who failed treatment with other agents and that all patients receiving LAAM should have baseline electrocardiogram (ECG) screening and periodic monitoring . Because most clinics were reluctant to initiate such ECG assessments, the use of LAAM (not very high to begin with), dropped sharply. In 2003, Roxane Laboratories, the sole distributor of LAAM, announced its decision to discontinue its sale. However, it remains an FDA-approved therapeutic agent."
Jaffe, Jerome, "Can LAAM, Like Lazarus, Come Back From the Dead" (Editorial), Addiction, Aug 9, 2007, Vol. 102, No. 9, p. 1342, doi:10.1111/j.1360-0443.2007.01976.x